Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 17

Showing 17 citing articles:

Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Schizophrenia Bulletin Open (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 12
Umbelliferone and Its Synthetic Derivatives as Suitable Molecules for the Development of Agents with Biological Activities: A Review of Their Pharmacological and Therapeutic Potential
Anita Kornicka, Łukasz Balewski, Monika Lahutta, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1732-1732
Open Access | Times Cited: 18
Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis
Anne Connolly, Phoebe Wallman, Olubanké Dzahini, et al.
Psychopharmacology (2024) Vol. 241, Iss. 2, pp. 225-241
Open Access | Times Cited: 5
The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis—The Case of the Xanomeline–Trospium Combination: A Systematic Review
Octavian Vasiliu, Beatrice Budeanu, Mihai-Ștefan Cătănescu
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 610-610
Open Access | Times Cited: 4
Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia
Ruri Okubo, Motohiro Okada, Eishi Motomura
Biomolecules (2024) Vol. 14, Iss. 9, pp. 1128-1128
Open Access | Times Cited: 4
Research Progress on MECT Combined with Second-Generation Antipsychotic Drugs in the Treatment of Schizophrenia
堃 杨
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 871-877
Closed Access
Schizophrenia Management: Systematic Review of Current Medications and Phase-3 Agents (2008–2024)
Salma Abdelmoteleb, Jayant Totlani, Salma Ramadan, et al.
Neuroscience Applied (2025) Vol. 4, pp. 105507-105507
Open Access
Novel pharmaceutical treatment approaches for schizophrenia: a systematic literature review
Anan S. Jarab, Walid Al‐Qerem, Adam Khdour, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access
Modulation of the human GlyT1 by clinical drugs and cholesterol
Na Li, Yiqing Wei, Renjie Li, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia
Christopher Zacker, Justin Puckett, Sachin Kamal-Bahl
ClinicoEconomics and Outcomes Research (2024) Vol. Volume 16, pp. 567-579
Open Access | Times Cited: 3
Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data
Konstantinos Ν. Fountoulakis, Mauricio Tohen, Carlos A. Zarate
European Neuropsychopharmacology (2024) Vol. 81, pp. 1-9
Closed Access | Times Cited: 2
Los receptores muscarínicos como potencial objetivo terapéutico en la esquizofrenia
José Eduardo López Villa
eNeurobiología (2024) Vol. 15, Iss. 38
Open Access | Times Cited: 1
Pharmacological Treatments of Negative Symptoms in Schizophrenia—An Update
Eva-Maria Tsapakis, Michael Treiber, Calypso Mitkani, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5637-5637
Open Access | Times Cited: 1
Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.
Waguih William IsHak, Ashley N. D. Meyer, Luiza Freire, et al.
PubMed (2024) Vol. 21, Iss. 7-9, pp. 27-47
Closed Access | Times Cited: 1
A New Antipsychotic for Schizophenia: Xanomeline and Trospium (Cobenfy)
Jeremy Mills
Issues in Mental Health Nursing (2024) Vol. 45, Iss. 12, pp. 1364-1367
Closed Access | Times Cited: 1
Pharmacologie et mode d’action des antipsychotiques
N. Franck, F. Fromager, F. Thibaut
Encyclopédie médico-chirurgicale. Psychiatrie (2015) Vol. 31, Iss. 1, pp. 1-17
Closed Access | Times Cited: 6
Global research in schizophrenia and serotonin: a bibliometric analysis
Gustavo Canul-Medina, Gael López-Pech, Francisco Jiménez‐Trejo
Frontiers in Psychiatry (2024) Vol. 15
Open Access
Page 1

Scroll to top